1. Home
  2. CING vs NBRG Comparison

CING vs NBRG Comparison

Compare CING & NBRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CING

Cingulate Inc.

HOLD

Current Price

$4.52

Market Cap

64.6M

Sector

Health Care

ML Signal

HOLD

NBRG

Newbridge Acquisition Limited Class A Ordinary Share

N/A

Current Price

$9.93

Market Cap

74.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CING
NBRG
Founded
2012
2021
Country
United States
Hong Kong
Employees
14
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
64.6M
74.5M
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
CING
NBRG
Price
$4.52
$9.93
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$34.50
N/A
AVG Volume (30 Days)
419.3K
100.0
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.20
$9.59
52 Week High
$11.89
$9.96

Technical Indicators

Market Signals
Indicator
CING
NBRG
Relative Strength Index (RSI) 39.58 63.89
Support Level $3.50 $9.90
Resistance Level $6.67 N/A
Average True Range (ATR) 0.39 0.01
MACD 0.01 0.01
Stochastic Oscillator 13.76 66.67

Price Performance

Historical Comparison
CING
NBRG

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

About NBRG Newbridge Acquisition Limited Class A Ordinary Share

Newbridge Acquisition Ltd is a blank check company.

Share on Social Networks: